Testing for Vector-Borne Infections
This BCBSOK Clinical Payment and Coding Policy (CPCP) outlines laboratory reimbursement criteria for testing of various vector-borne infections and specifies which tests may or may not be reimbursable for covered individuals and products.
Reimbursement Information revised completely and reorganized in alphabetical order based on infection name; Zika virus language moved from CPCPLAB042 into this document and items 18-21 added for Zika virus.
Reimbursement information revised for clarity and signs and symptoms for each disease added to Notes referenced in each position statement.
Policy updated with literature review and references revised.
Document created as new policy on 11/1/2022.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.